- Home
- BTCS vs CHRS Comparison
BTCS vs CHRS Comparison
Compare BTCS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTCS
- CHRS
- Stock Information
- Founded
- BTCS 2008
- CHRS 2010
- Country
- BTCS United States
- CHRS United States
- Employees
- BTCS N/A
- CHRS N/A
- Industry
- BTCS Finance: Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTCS Finance
- CHRS Health Care
- Exchange
- BTCS Nasdaq
- CHRS Nasdaq
- Market Cap
- BTCS 218.2M
- CHRS 186.0M
- IPO Year
- BTCS N/A
- CHRS 2014
- Fundamental
- Price
- BTCS $3.07
- CHRS $1.49
- Analyst Decision
- BTCS Strong Buy
- CHRS Strong Buy
- Analyst Count
- BTCS 1
- CHRS 4
- Target Price
- BTCS $7.00
- CHRS $4.51
- AVG Volume (30 Days)
- BTCS 2.1M
- CHRS 1.0M
- Earning Date
- BTCS 11-11-2025
- CHRS 11-06-2025
- Dividend Yield
- BTCS 1.52%
- CHRS N/A
- EPS Growth
- BTCS N/A
- CHRS N/A
- EPS
- BTCS N/A
- CHRS 1.55
- Revenue
- BTCS $7,522,073.00
- CHRS $272,209,000.00
- Revenue This Year
- BTCS $160.41
- CHRS N/A
- Revenue Next Year
- BTCS $46.15
- CHRS $109.48
- P/E Ratio
- BTCS N/A
- CHRS $1.01
- Revenue Growth
- BTCS 354.52
- CHRS 52.33
- 52 Week Low
- BTCS $1.21
- CHRS $0.66
- 52 Week High
- BTCS $8.49
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BTCS 31.26
- CHRS 40.79
- Support Level
- BTCS $3.07
- CHRS $1.39
- Resistance Level
- BTCS $4.30
- CHRS $1.61
- Average True Range (ATR)
- BTCS 0.23
- CHRS 0.11
- MACD
- BTCS -0.10
- CHRS -0.04
- Stochastic Oscillator
- BTCS 3.90
- CHRS 22.09
About BTCS BTCS Inc.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.